The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review

IF 2.9 3区医学 Q2 ONCOLOGY Clinical breast cancer Pub Date : 2024-08-01 DOI:10.1016/j.clbc.2024.03.009

{"title":"The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review","authors":"","doi":"10.1016/j.clbc.2024.03.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The association of FGFR2-rs13387042 polymorphism with breast cancer (BC) susceptibility in women remains inconclusive due to varying reports. In this study, we conducted a meta-analysis to explore the relationship between FGFR2-rs13387042 polymorphism and susceptibility to BC.</p></div><div><h3>Methods</h3><p>Relevant literature were acquired through searches across multiple databases. Odds ratio (OR) values were pooled to assess the risk of BC for different alleles and genotypes. The heterogeneity among the included literature was evaluated. Sensitivity analysis was used to verify the stability of the results. Egger's linear regression test was used to assess the significance of publication bias of the included literature.</p></div><div><h3>Results</h3><p>A total of 17 publications were included, encompassing 122,607 cases and 175,966 controls. There was significantly increased risk of BC for allele A compared with G (OR = 1.15, 95% CI = 1.14-1.67, <em>P</em> < .001), genotype AA compared with GG (OR = 1.34, 95% CI = 1.29-1.38, <em>P</em> < .001), and genotype GA compared with GG (OR = 1.19, 95% CI = 1.12-1.26, <em>P</em> < .001). Both Egger's test and funnel plot indicated the presence of publication bias. After adjusting potential publication bias by the trim-and-fill method, the comparison of allele A versus G (OR = 1.15, 95% CI = 1.13-1.17, <em>P</em> < .001), genotype AA versus GG (OR = 1.32, 95% CI = 1.28-1.37, <em>P</em> < .001), and genotype GA versus GG (OR = 1.15, 95% CI = 1.09-1.22, <em>P</em> < .001) remained statistically significant. In various subgroups, the allele A showed significantly higher risk of BC upon allele G in estrogen receptor (ER) positive BC, ER negative BC, progesterone receptor (PR) positive BC, PR negative BC, triple-negative BC, pathological grade I BC, grade II BC, and grade III breast cancer. The subsequent sensitivity analysis suggested the above findings stable and reliable.</p></div><div><h3>Conclusion</h3><p>In this study, we found that the allele A of the FGFR2-rs13387042 polymorphism is associated with increased risk of developing breast cancer. This study underscores its potential as a genetic marker for personalized risk assessment and targeted interventions.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"24 6","pages":"Pages 552-561"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S152682092400082X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The association of FGFR2-rs13387042 polymorphism with breast cancer (BC) susceptibility in women remains inconclusive due to varying reports. In this study, we conducted a meta-analysis to explore the relationship between FGFR2-rs13387042 polymorphism and susceptibility to BC.

Methods

Relevant literature were acquired through searches across multiple databases. Odds ratio (OR) values were pooled to assess the risk of BC for different alleles and genotypes. The heterogeneity among the included literature was evaluated. Sensitivity analysis was used to verify the stability of the results. Egger's linear regression test was used to assess the significance of publication bias of the included literature.

Results

A total of 17 publications were included, encompassing 122,607 cases and 175,966 controls. There was significantly increased risk of BC for allele A compared with G (OR = 1.15, 95% CI = 1.14-1.67, P < .001), genotype AA compared with GG (OR = 1.34, 95% CI = 1.29-1.38, P < .001), and genotype GA compared with GG (OR = 1.19, 95% CI = 1.12-1.26, P < .001). Both Egger's test and funnel plot indicated the presence of publication bias. After adjusting potential publication bias by the trim-and-fill method, the comparison of allele A versus G (OR = 1.15, 95% CI = 1.13-1.17, P < .001), genotype AA versus GG (OR = 1.32, 95% CI = 1.28-1.37, P < .001), and genotype GA versus GG (OR = 1.15, 95% CI = 1.09-1.22, P < .001) remained statistically significant. In various subgroups, the allele A showed significantly higher risk of BC upon allele G in estrogen receptor (ER) positive BC, ER negative BC, progesterone receptor (PR) positive BC, PR negative BC, triple-negative BC, pathological grade I BC, grade II BC, and grade III breast cancer. The subsequent sensitivity analysis suggested the above findings stable and reliable.

Conclusion

In this study, we found that the allele A of the FGFR2-rs13387042 polymorphism is associated with increased risk of developing breast cancer. This study underscores its potential as a genetic marker for personalized risk assessment and targeted interventions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

FGFR2 变异 rs13387042 与乳腺癌风险有关：一项荟萃分析和系统综述

FGFR2-rs13387042多态性与女性乳腺癌（BC）易感性的关系因报道不同而仍无定论。在本研究中，我们进行了一项荟萃分析，以探讨 FGFR2-rs13387042 多态性与乳腺癌易感性之间的关系。我们在多个数据库中检索了相关文献。对不同等位基因和基因型的比值（OR）进行汇总，以评估 BC 的风险。对纳入文献的异质性进行了评估。采用敏感性分析来验证结果的稳定性。采用Egger线性回归检验来评估纳入文献的发表偏倚的显著性。共纳入了 17 篇文献，涉及 122,607 例病例和 175,966 例对照。等位基因A与G相比（OR=1.15，95% CI=1.14-1.67，P<0.001），基因型AA与GG相比（OR=1.34，95% CI=1.29-1.38，P<0.001），基因型GA与GG相比（OR=1.19，95% CI=1.12-1.26，P<0.001），罹患BC的风险明显增加。Egger检验和漏斗图均显示存在发表偏倚。通过修剪填充法调整潜在的发表偏倚后，等位基因 A 与 G 的比较（OR=1.15，95% CI=1.13-1.17，P<0.001）、基因型 AA 与 GG 的比较（OR=1.32，95% CI=1.28-1.37，P<0.001）和基因型 GA 与 GG 的比较（OR=1.15，95% CI=1.09-1.22，<0.001）仍具有统计学意义。在不同的亚组中，等位基因 A 在雌激素受体（ER）阳性 BC、ER 阴性 BC、孕激素受体（PR）阳性 BC、PR 阴性 BC、三阴性 BC、病理分级 I 级 BC、II 级 BC 和 III 级乳腺癌中的 BC 风险明显高于等位基因 G。随后的敏感性分析表明，上述结果稳定可靠。在这项研究中，我们发现 FGFR2-rs13387042 多态性的等位基因 A 与乳腺癌发病风险的增加有关。这项研究强调了其作为个性化风险评估和针对性干预的遗传标记的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.

期刊最新文献

Editorial Board Table of Contents Clinical and Imaging Features Associated With Malignant Focal Nonmass Enhancement on Breast MRI. Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?